Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target

Aggressive natural killer-cell leukemia (ANKL) has few targeted therapies. Here ANKL patients are reported to harbor STAT3, RAS-MAPK pathway, DDX3X and epigenetic modifier mutations; and drug sensitivity profiling uncovers the importance of the JAK-STAT pathway, revealing potential ANKL therapeutic...

Full description

Bibliographic Details
Main Authors: Olli Dufva, Matti Kankainen, Tiina Kelkka, Nodoka Sekiguchi, Shady Adnan Awad, Samuli Eldfors, Bhagwan Yadav, Heikki Kuusanmäki, Disha Malani, Emma I Andersson, Paavo Pietarinen, Leena Saikko, Panu E. Kovanen, Teija Ojala, Dean A. Lee, Thomas P. Loughran, Hideyuki Nakazawa, Junji Suzumiya, Ritsuro Suzuki, Young Hyeh Ko, Won Seog Kim, Shih-Sung Chuang, Tero Aittokallio, Wing C. Chan, Koichi Ohshima, Fumihiro Ishida, Satu Mustjoki
Format: Article
Language:English
Published: Nature Publishing Group 2018-04-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-018-03987-2
id doaj-a90516e221ea4f0c9791e1e130cc3ead
record_format Article
spelling doaj-a90516e221ea4f0c9791e1e130cc3ead2021-05-11T09:22:41ZengNature Publishing GroupNature Communications2041-17232018-04-019111210.1038/s41467-018-03987-2Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic targetOlli Dufva0Matti Kankainen1Tiina Kelkka2Nodoka Sekiguchi3Shady Adnan Awad4Samuli Eldfors5Bhagwan Yadav6Heikki Kuusanmäki7Disha Malani8Emma I Andersson9Paavo Pietarinen10Leena Saikko11Panu E. Kovanen12Teija Ojala13Dean A. Lee14Thomas P. Loughran15Hideyuki Nakazawa16Junji Suzumiya17Ritsuro Suzuki18Young Hyeh Ko19Won Seog Kim20Shih-Sung Chuang21Tero Aittokallio22Wing C. Chan23Koichi Ohshima24Fumihiro Ishida25Satu Mustjoki26Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer CenterInstitute for Molecular Medicine Finland (FIMM), University of HelsinkiHematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer CenterDepartment of Comprehensive Cancer Therapy, Shinshu University School of MedicineHematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer CenterInstitute for Molecular Medicine Finland (FIMM), University of HelsinkiHematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer CenterHematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer CenterInstitute for Molecular Medicine Finland (FIMM), University of HelsinkiHematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer CenterHematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer CenterDepartment of Pathology, HUSLAB and Haartman Institute, University of Helsinki and Helsinki University HospitalDepartment of Pathology, HUSLAB and Haartman Institute, University of Helsinki and Helsinki University HospitalPharmacology, Faculty of Medicine, University of HelsinkiNationwide Children’s Hospital, Division of Hematology, Oncology, and BMTDepartment of Medicine, University of VirginiaDivision of Hematology, Internal Medicine, Shinshu University School of MedicineDepartment of Oncology/Hematology, Shimane University HospitalDepartment of Oncology/Hematology, Shimane University HospitalDepartment of Pathology, Samsung Medical CenterSungkyunkwan University School of Medicine, Samsung Medical CenterDepartment of Pathology, Chi-Mei Medical CenterInstitute for Molecular Medicine Finland (FIMM), University of HelsinkiDepartment of Pathology, City of Hope National Medical CenterDepartment of Pathology, Kurume University School of MedicineDepartment of Biomedical Laboratory Sciences, Shinshu University School of MedicineHematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer CenterAggressive natural killer-cell leukemia (ANKL) has few targeted therapies. Here ANKL patients are reported to harbor STAT3, RAS-MAPK pathway, DDX3X and epigenetic modifier mutations; and drug sensitivity profiling uncovers the importance of the JAK-STAT pathway, revealing potential ANKL therapeutic targets.https://doi.org/10.1038/s41467-018-03987-2
collection DOAJ
language English
format Article
sources DOAJ
author Olli Dufva
Matti Kankainen
Tiina Kelkka
Nodoka Sekiguchi
Shady Adnan Awad
Samuli Eldfors
Bhagwan Yadav
Heikki Kuusanmäki
Disha Malani
Emma I Andersson
Paavo Pietarinen
Leena Saikko
Panu E. Kovanen
Teija Ojala
Dean A. Lee
Thomas P. Loughran
Hideyuki Nakazawa
Junji Suzumiya
Ritsuro Suzuki
Young Hyeh Ko
Won Seog Kim
Shih-Sung Chuang
Tero Aittokallio
Wing C. Chan
Koichi Ohshima
Fumihiro Ishida
Satu Mustjoki
spellingShingle Olli Dufva
Matti Kankainen
Tiina Kelkka
Nodoka Sekiguchi
Shady Adnan Awad
Samuli Eldfors
Bhagwan Yadav
Heikki Kuusanmäki
Disha Malani
Emma I Andersson
Paavo Pietarinen
Leena Saikko
Panu E. Kovanen
Teija Ojala
Dean A. Lee
Thomas P. Loughran
Hideyuki Nakazawa
Junji Suzumiya
Ritsuro Suzuki
Young Hyeh Ko
Won Seog Kim
Shih-Sung Chuang
Tero Aittokallio
Wing C. Chan
Koichi Ohshima
Fumihiro Ishida
Satu Mustjoki
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
Nature Communications
author_facet Olli Dufva
Matti Kankainen
Tiina Kelkka
Nodoka Sekiguchi
Shady Adnan Awad
Samuli Eldfors
Bhagwan Yadav
Heikki Kuusanmäki
Disha Malani
Emma I Andersson
Paavo Pietarinen
Leena Saikko
Panu E. Kovanen
Teija Ojala
Dean A. Lee
Thomas P. Loughran
Hideyuki Nakazawa
Junji Suzumiya
Ritsuro Suzuki
Young Hyeh Ko
Won Seog Kim
Shih-Sung Chuang
Tero Aittokallio
Wing C. Chan
Koichi Ohshima
Fumihiro Ishida
Satu Mustjoki
author_sort Olli Dufva
title Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
title_short Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
title_full Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
title_fullStr Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
title_full_unstemmed Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
title_sort aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight jak-stat signaling as therapeutic target
publisher Nature Publishing Group
series Nature Communications
issn 2041-1723
publishDate 2018-04-01
description Aggressive natural killer-cell leukemia (ANKL) has few targeted therapies. Here ANKL patients are reported to harbor STAT3, RAS-MAPK pathway, DDX3X and epigenetic modifier mutations; and drug sensitivity profiling uncovers the importance of the JAK-STAT pathway, revealing potential ANKL therapeutic targets.
url https://doi.org/10.1038/s41467-018-03987-2
work_keys_str_mv AT ollidufva aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT mattikankainen aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT tiinakelkka aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT nodokasekiguchi aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT shadyadnanawad aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT samulieldfors aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT bhagwanyadav aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT heikkikuusanmaki aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT dishamalani aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT emmaiandersson aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT paavopietarinen aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT leenasaikko aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT panuekovanen aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT teijaojala aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT deanalee aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT thomasploughran aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT hideyukinakazawa aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT junjisuzumiya aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT ritsurosuzuki aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT younghyehko aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT wonseogkim aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT shihsungchuang aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT teroaittokallio aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT wingcchan aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT koichiohshima aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT fumihiroishida aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
AT satumustjoki aggressivenaturalkillercellleukemiamutationallandscapeanddrugprofilinghighlightjakstatsignalingastherapeutictarget
_version_ 1721450017451933696

Similar Items